本文由定制化的企业情报智能服务平台——【情报强企】提供

标签：#cell therapy

新兴的细胞疗法生物技术公司Cellergy Pharma获得了30万美元的奖金，用于推动治疗严重过敏性疾病的疗法的开发。

Cellergy Pharma,a rising cellular therapies biotechnology company, has been awarded $300,000 to fuel the development of therapies to treat severe allergic diseases.

本月早些时候，这家成立两年的公司获得了美国国家过敏和传染病研究所的资助，用于开发CAR-T细胞疗法。Cellergy Pharma总部位于杜邦实验站园区的Delaware Innovation Space，并参加了Delaware BioScience Association2023的演讲比赛。

The two-year old company was awarded funding from National Institute of Allergy and Infectious Diseases earlier this month to develop CAR-T cell therapies. Cellergy Pharma is based out of theDelaware Innovation Spaceon the DuPont Experimental Station campus, and participated in theDelaware BioScience Association2023 pitch competition.

Cellergy Pharma总裁罗纳德·杜德克在一份声明中表示：“这项拨款是对Cellergy专注于开发CAR-T细胞治疗严重特应性过敏性疾病的重要性的认可。”。“我们期待着与我们的合作伙伴Nemours Children’s Health进行这项开创性的研究。”

“This grant award is an acknowledgement of the importance of Cellergy’s focus to develop CAR-T cells for treating severe atopic allergic diseases,” Cellergy Pharma President Ronald Dudek said in a statement. “We look forward to conducting this groundbreaking research with our partner Nemours Children’s Health.”

CAR-T治疗通常包括从患者体内提取白细胞，即T细胞，并对其进行重新设计以攻击癌症，然后将其输回体内。

CAR-T treatments generally involve extracting white blood cells, known as T-cells, from a patient and re-engineering them to attack cancer and infusing them back into the body.

2017年，美国食品药品监督管理局批准了第一种治疗白血病的药物。从那时起，六种不同的CAR-T疗法已被批准用于治疗各种血癌。

The first FDA approval for this type of therapy was approved in 2017 to treat leukemia. Since then, six different CAR-T therapies have been approved to treat various blood cancers.

但Cellergy Pharma选择将这项突破性研究超越治疗癌症。在四届CAR-T细胞初创公司创始人杜德克的指导下，该公司设想了一种一次性免疫疗法，可以消除哮喘或食物过敏症状。

But Cellergy Pharma is opting to take that groundbreaking research beyond treating cancer. With the guidance of Dudek, who is a four-time CAR-T cell startup founder, the company imagines a one-time immunotherapy that can eliminate asthma or food allergy symptoms.

Cellergy Pharma的数据显示，目前有2100万成年人患有哮喘，其中不到100万人被认定为不受控制和严重哮喘。该公司的成人食物过敏二级市场约有2600万人，其中230万人在一年内至少经历过一次与过敏相关的急诊就诊。

There are 21 million adults with asthma, with less than a million qualified as uncontrolled and severe, according to Cellergy Pharma. The company’s secondary market of adults with food allergies is roughly 26 million — with 2.3 million people who had experienced at least one allergy-related emergency department visit within a year.

目前，Cellergy Pharma的主要产品是CP-010，它靶向免疫球蛋白E，这是一种与过敏反应相关的关键抗体。Cellergy Pharma首席科学官Mark Ma在领导Nemours Children’s Health免疫学研究实验室期间，一直致力于发明该公司的CAR-T细胞受体。

Right now, Cellergy Pharma,’s lead product is CP-010, which targets immunoglobulin E, a key antibody associated with allergic reactions. The research Cellergy Pharma Chief Science Officer Mark Ma has worked in inventing the company’s CAR-T cell receptors, amid his work leading the immunology research laboratory at Nemours Children’s Health.

马在一份新闻声明中表示：“我们非常感谢获得这一赠款，这将推动CP-010的开发，这是一种靶向膜IgE的自体CAR T细胞产品。这一奖项将资助我们进入位于威尔明顿创新空间的新研究实验室。”

“We are grateful for the receipt of this grant award, which will advance the developmentCP-010, an autologous CAR T cell product that targets membrane IgE. This award will fund our move into our new research lab at the Innovation Space in Wilmington,” Ma said in a press statement.

本文来源于网络资料，由【情报强企】整理